Skip to main content
    B

    Bio-Techne Corp (TECH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $72.79
    -0.01 (-0.01%)

    Market Cap: $11.44B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Bio-Techne Corp (TECH) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Bio-Techne (TECH) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Bio-Techne reported EPS of $0.36, below the $0.40 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    +5.47%

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.48
    Range$0.46 - $0.51
    7 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.48+0.0%
    60d ago$0.47+1.7%
    30d ago$0.48+0.2%
    7d ago$0.48+0.2%
    Current$0.48
    Revenue Consensus
    $308.14M
    Range$303.67M - $313.28M
    8 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.56
    Range$0.55 - $0.59
    7 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.56+0.5%
    60d ago$0.55+1.8%
    30d ago$0.56-0.1%
    7d ago$0.56+0.2%
    Current$0.56
    Revenue Consensus
    $328.49M
    Range$323.30M - $334.77M
    8 analysts

    Next Report

    TECH has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 4.3% above the $0.46 reported for the quarter ended Dec 31, 2025.

    TECH Earnings Call

    The latest TECH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, TECH beat 26, missed 9 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $299.71M, up 4.6% from $286.56M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.36$0.40N/A-10.00%Miss0.0%70 up, 1 downNov 3, 2026$299.71M
    Jun 30, 2026$0.49$0.46N/A+6.52%Beat-7.5%110 up, 1 downAug 12, 2026$321.19M
    Mar 31, 2026$0.53$0.53$0.51 - $0.560.00%In line-5.4%121 up, 8 downMay 6, 2026$311.42M
    Dec 31, 2025$0.46$0.43$0.41 - $0.46+6.98%Beat+9.5%120 up, 1 downFeb 4, 2026$295.88M
    Sep 30, 2025$0.36$0.36N/A0.00%In line-14.3%130 up, 2 downNov 5, 2025$286.56M
    Jun 30, 2025$0.53$0.50$0.47 - $0.52+6.00%Beat+8.2%150 up, 1 downAug 6, 2025$316.96M
    Mar 31, 2025$0.56$0.51$0.49 - $0.52+9.80%Beat+16.7%111 up, 2 downMay 7, 2025$316.18M
    Dec 31, 2024$0.42$0.39$0.36 - $0.40+7.69%Beat+5.0%114 up, 4 downFeb 5, 2025$297.03M
    Sep 30, 2024$0.42$0.38$0.35 - $0.42+10.53%Beat+2.4%130 up, 0 downOct 30, 2024$289.46M
    Jun 30, 2024$0.49$0.49$0.46 - $0.520.00%In line-10.9%130 up, 0 downAug 7, 2024$306.10M
    Mar 31, 2024$0.48$0.46$0.42 - $0.50+4.35%Beat-9.4%121 up, 1 downMay 1, 2024$303.43M
    Dec 31, 2023$0.40$0.41$0.38 - $0.45-2.44%Miss-14.9%120 up, 0 downFeb 1, 2024$272.60M
    Sep 30, 2023$0.41$0.44$0.41 - $0.48-6.82%Miss-8.9%120 up, 0 downOct 31, 2023$276.94M
    Jun 30, 2023$0.55$0.55$0.53 - $0.570.00%In line+7.8%120 up, 0 downAug 8, 2023$301.32M
    Mar 31, 2023$0.53$0.53$0.50 - $0.540.00%In line-1.9%122 up, 0 downMay 3, 2023$294.15M
    Dec 31, 2022$0.47$0.49$0.46 - $1.96-4.08%Miss0.0%110 up, 1 downFeb 2, 2023$271.58M
    Sep 30, 2022$0.45$0.46$0.44 - $0.48-2.17%Miss-2.2%100 up, 2 downNov 1, 2022$269.65M
    Jun 30, 2022$0.51$0.52N/A-1.92%Miss+8.5%N/A0 up, 1 downAug 4, 2022$288.23M
    Mar 31, 2022$0.54$0.50$0.49 - $0.51+8.00%Beat+20.0%100 up, 1 downMay 4, 2022$290.38M
    Dec 31, 2021$0.47$0.45$0.43 - $0.47+4.44%Beat+14.6%10N/AFeb 1, 2022$269.28M
    Sep 30, 2021$0.46$0.43$0.38 - $0.49+6.98%Beat+27.8%101 up, 0 downNov 2, 2021$257.72M
    Jun 30, 2021$0.47$0.43$0.36 - $0.45+9.30%Beat+88.0%10N/AAug 5, 2021$259.03M
    Mar 31, 2021$0.45$0.39$0.36 - $0.42+15.38%Beat+28.6%10N/AMay 6, 2021$243.55M
    Dec 31, 2020$0.41$0.34$0.32 - $0.37+20.59%Beat+51.9%10N/AFeb 2, 2021$224.25M
    Sep 30, 2020$0.36$0.28$0.25 - $0.30+28.57%Beat+33.3%9N/ANov 5, 2020$204.20M
    Jun 30, 2020$0.25$0.19$0.17 - $0.22+31.58%Beat-19.4%8N/AAug 4, 2020$175.83M
    Mar 31, 2020$0.35$0.28$0.22 - $0.32+25.00%Beat+16.7%8N/AApr 30, 2020$194.68M
    Dec 31, 2019$0.27$0.28$0.28 - $0.29-3.57%Miss0.0%8N/AFeb 4, 2020$184.93M
    Sep 30, 2019$0.27$0.26$0.25 - $0.28+3.85%Beat+8.0%4N/AOct 29, 2019$183.24M
    Jun 30, 2019$0.31$0.33$0.31 - $0.34-6.06%Miss-8.8%6N/AAug 6, 2019$191.66M
    Mar 31, 2019$0.30$0.29$0.27 - $0.30+3.45%Beat0.0%7N/AApr 30, 2019$184.86M
    Dec 31, 2018$0.27$0.25$0.23 - $0.29+8.00%Beat+3.8%8N/AFeb 5, 2019$174.51M
    Sep 30, 2018$0.25$0.24$0.22 - $0.27+4.17%Beat+8.7%8N/AOct 30, 2018$162.97M
    Jun 30, 2018$0.34$0.32$0.31 - $0.34+6.25%Beat+25.9%8N/AAug 7, 2018$180.25M
    Mar 31, 2018$0.30$0.29$0.27 - $0.30+3.45%Beat+25.0%8N/AMay 2, 2018$163.97M
    Dec 31, 2017$0.26$0.23$0.22 - $0.24+13.04%Beat+30.0%9N/AFeb 6, 2018$154.15M
    Sep 30, 2017$0.23$0.22$0.21 - $0.23+4.55%Beat+9.5%9N/AOct 31, 2017$144.61M
    Jun 30, 2017$0.27$0.25$0.24 - $0.25+8.00%Beat+17.4%9N/AAug 8, 2017$156.58M
    Mar 31, 2017$0.24$0.23N/A+4.35%Beat-4.0%N/AN/AMay 2, 2017$144.04M
    Dec 31, 2016$0.20$0.21N/A-4.76%Miss-9.1%N/AN/AFeb 7, 2017$131.81M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Jun 30, 2026 was $1.84, down 4.7% from the year before. It was $0.92 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Jun 30, 2026$1.84-4.7%
    Jun 30, 2025$1.93+8.4%
    Jun 30, 2024$1.78-11.0%
    Jun 30, 2023$2.00N/A
    Jun 30, 2022$1.98+17.2%
    Jun 30, 2021$1.69+48.2%
    Jun 30, 2020$1.14N/A
    Jun 30, 2019$1.13N/A
    Jun 30, 2018$1.13+22.8%
    Jun 30, 2017$0.92N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,200 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,20210
    2026Q2Jun 30, 20267,55211
    2026Q1Mar 31, 20267,17713
    2025Q4Dec 31, 20257,36213
    2025Q3Sep 30, 20257,49812
    2025Q2Jun 30, 20258,23713
    2025Q1Mar 31, 20257,64912
    2024Q4Dec 31, 20247,82013

    2026Q3 Earnings Call

    Opening remarks

    David Clair Vice President, Investor Relations Good morning, and thank you for joining us. On the call with me this morning are Kim Kelderman, President and Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company's future results. The company's 10-K for fiscal 2025 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K as well as the company's other SEC filings are available on the company's website within its Investor Relations section. During the call, non-GAAP financial measures may be used to provide information pertinent to ongoing business performance. Tables reconciling these measures to most comparable GAAP measures are available in the company's press release issued earlier this morning on the Investor Relations section of our Bio-Techne Corporation website at www.bio-techne.com. Separately, in the coming weeks, we will be participating in the Bank of America and Jefferies Healthcare Conferences. We look forward to connecting with many of you at these upcoming events. I will now turn the call over to Kim.

    Kim Kelderman President and Chief Executive Officer Thank you, Dave, and good morning, everyone. Welcome to Bio-Techne's Third Quarter Earnings Call for Fiscal 2026. The Bio-Techne team continued to execute with discipline in a dynamic and uneven end market environment. Our quarterly performance was supported by sustained strength from our large pharmaceutical customers and stable to improving trends in our U.S. academic end market. These positives were partially offset by continued softness in emerging biotech spending, resulting in a 2% organic revenue decline for the quarter. Importantly, we are seeing encouraging indicators that point to an ongoing improvement in the U.S. academia and an eventual recovery in emerging biotech, which positions us well for a stronger fiscal 2027. As discussed in our prior earnings call, order timing related to two cell therapy customers that received FDA Fast Track Designation along with the timing of a large OEM commercial supply order created a 400 basis point headwind in the quarter. Excluding these factors, underlying organic revenue growth was 2%. There were several notable highlights during our third quarter, including the following: our Spatial Biology portfolio delivered mid-teens growth and exited the quarter with another record backlog for our COMET platform. Our GMP protein portfolio grew nearly 50% year-over-year when excluding the two fast track cell therapy customers. Within our Proteomic Analysis franchise, favorable instrument placements and utilization trends drove mid-single-digit growth.

    Frequently Asked Questions About TECH

    When is Bio-Techne's next earnings date?

    Bio-Techne's next earnings report is expected for Feb 2, 2027.

    Did TECH beat earnings estimates last quarter?

    No. Bio-Techne reported EPS of $0.36 for the quarter ended Sep 30, 2026, below the $0.40 estimate by 10.00%.

    What EPS do analysts expect from TECH next quarter?

    The consensus EPS estimate for Bio-Techne for the quarter ending Dec 31, 2026 is $0.48 from 7 analysts, with estimates from $0.46 to $0.51.

    How often does TECH beat earnings estimates?

    Bio-Techne beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.37%.